HB 975 establishes the "right to try" cutting-edge treatments for patients with life-threatening or severely debilitating illnesses. It allows patients, under certain conditions, to access investigational drugs, biological products, or devices tailored to their genetic profile. Patients must have considered all other FDA-approved options and provide informed consent. The bill protects providers and manufacturers from liability under certain conditions and ensures that heirs are not liable for treatment-related costs after the patient’s death. The law takes effect on September 1, 2025​